| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PLEKHA3 |
| Uniprot No | Q9HB20 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-300 aa |
| 活性数据 | MEGVLYKWTN YLTGWQPRWF VLDNGILSYY DSQDDVCKGS KGSIKMAVCE IKVHSADNTR MELIIPGEQH FYMKAVNAAE RQRWLVALGS SKACLTDTRT KKEKEISETS ESLKTKMSEL RLYCDLLMQQ VHTIQEFVHH DENHSSPSAE NMNEASSLLS ATCNTFITTL EECVKIANAK FKPEMFQLHH PDPLVSPVSP SPVQMMKRSV SHPGSCSSER SSHSIKEPVS TLHRLSQRRR RTYSDTDSCS DIPLEDPDRP VHCSKNTLNG DLASATIPEE SRLMAKKQSE SEDTLPSFSS |
| 分子量 | 33.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为模拟生成的关于重组人PLEKHA3蛋白的研究文献示例。**请注意文献信息为虚构**，实际文献需通过PubMed、Google Scholar等平台检索：
---
1. **文献名称**: *"Recombinant Human PLEKHA3 Promotes Tumor Cell Invasion via PI3K/AKT Signaling"*
**作者**: Zhang Y. et al. (2018)
**摘要**: 该研究在大肠杆菌系统中成功表达了重组人PLEKHA3蛋白，并证实其通过激活PI3K/AKT信号通路增强乳腺癌细胞的迁移和侵袭能力，为靶向肿瘤治疗的分子机制提供了新依据。
---
2. **文献名称**: *"Structural Characterization of Recombinant PLEKHA3 and Its PH Domain Interaction with Phospholipids"*
**作者**: Johnson R.B., Smith K. (2020)
**摘要**: 通过X射线晶体学解析了重组人PLEKHA3蛋白的PH结构域三维结构，揭示了其与细胞膜磷脂PIP3的特异性结合模式，暗示其在细胞膜定位和信号转导中的关键作用。
---
3. **文献名称**: *"High-Yield Purification and Functional Analysis of Recombinant PLEKHA3 in Inflammatory Response"*
**作者**: Müller S. et al. (2019)
**摘要**: 开发了一种基于HEK293哺乳动物表达系统的重组PLEKHA3纯化方法，实验表明该蛋白通过调控NF-κB通路参与巨噬细胞的炎症反应，为免疫调控研究提供工具蛋白。
---
4. **文献名称**: *"PLEKHA3 Knockdown Suppresses Hepatocellular Carcinoma Metastasis via F-Actin Remodeling"*
**作者**: Li H. et al. (2021)
**摘要**: 利用重组PLEKHA3蛋白进行功能补偿实验，发现其缺失可通过重构细胞骨架F-actin抑制肝癌细胞转移，提示其在癌症靶向治疗中的潜在价值。
---
**提示**：实际研究中建议使用关键词 *"recombinant PLEKHA3"* 或 *"PLEKHA3 overexpression"* 检索文献，并优先选择近5年发表于 *Journal of Biological Chemistry*、*Oncogene* 等期刊的研究。
Recombinant human PLEKHA3 protein is a genetically engineered form of the pleckstrin homology (PH) domain-containing protein family member encoded by the *PLEKHA3* gene. PLEKHA3 contains a central PH domain, which facilitates interactions with phosphoinositides and membranes, suggesting roles in intracellular signaling or membrane trafficking. While its precise biological functions remain under investigation, studies associate PLEKHA3 with cellular processes such as vesicle transport, cytoskeletal organization, and cell adhesion. Dysregulation of PLEKHA3 has been tentatively linked to cancer progression and neurological disorders, though mechanistic insights are limited.
Recombinant PLEKHA3 is typically produced in expression systems like *E. coli* or mammalian cell lines, enabling scalable purification for functional studies. Its production allows researchers to analyze structure-function relationships, binding partners, and signaling pathways in vitro. Recent interest in PLEKHA3 stems from its potential as a biomarker or therapeutic target, particularly in cancers where its expression correlates with metastasis or drug resistance. However, further validation through proteomic and in vivo models is needed to clarify its pathophysiological relevance. Current research focuses on elucidating its interactions with kinases, GTPases, and lipid mediators to expand understanding of PH domain protein networks.
×
